Biology subjects

Quentin-Froignant, C.

Publications and source records attributed to Quentin-Froignant, C..

3 recordsLinked to original sources

bioRxiv2025

Use of ANCHOR viruses to validate radiative, physical and chemical decontamination systems in operational conditions.

ANCHOR tagged viruses provide a high-performance platform for the rapid evaluation of disinfection methods across chemical, radiative, and physical modalities. This study highlights the robustness of Vaccinia virus (VACV) and human Adenovirus type 5 (hAdV5) as environmental persistence models, demonstrating their suitability for testing disinfection protocols. ANCHOR imaging capability allows real-time visualization of disinfection efficacy, enabling rapid calibration and cost-effective validation of new disinfection systems. This technology provides essential support for the development and optimization of disinfection solutions in public areas up to the improvement of safety protocols in high-containment laboratories. The increasing number of BSL-4 laboratories worldwide underscores the critical needs for efficient and reliable decontamination systems and methods to test them in operational conditions to ensure biohazard safety. HighlightsO_LIANCHOR-tagged viruses provide a rapid and cost-effective platform for evaluating disinfection methods across chemical, physical, and radiative modalities. C_LIO_LIHuman Adenovirus type 5 (hAdV5) and Vaccinia virus (VACV) serve as robust environmental persistence models for testing viral decontamination protocols. C_LIO_LIThe use of ANCHOR viruses enables rapid real-time visualization of disinfection efficacy, improving safety validation in high-containment laboratories and public health applications. C_LI

microbiology↗

bioRxiv2025

LAVR-289, a New Orally Bioavailable Inhibitor of Adenovirus Replication in vitro and in vivo.

Adenoviruses are responsible for a range of pathologies, including respiratory infections in children, accounting for 5-10% of such cases. Although most adenovirus infections are self-resolving, they can cause serious illness, particularly in immunocompromised individuals. There is currently no approved treatment for adenovirus infections, although various therapeutic approaches are under investigation, including nucleoside analog inhibitors of replication. However, these treatments have shown limited efficacy. In this study, we report on the antiviral activity of LAVR-289, a broad-spectrum acyclonucleoside phosphonate exhibiting potent in vitro efficacy against several adenovirus serotypes, comparable to that of brincidofovir. LAVR-289 specifically inhibits viral replication, blocking the formation of viral replication centers and preventing late protein expression without affecting viral entry or delivery of viral genomes to the nucleus. In vivo using immunocompromised Syrian hamsters infected with HAdV-C6, oral administration of LAVR-289 resulted in 100% animal survival. These results suggest that LAVR-289 holds promise as a potential therapy for adenovirus infections, particularly in immunocompromised patients. HighlightsO_LILAVR-289 is a unique acyclic nucleoside phosphonate prodrug. C_LIO_LILAVR-289 displays antiviral activity against Adenovirus with an EC50 of about 100 nM against HAdV-C5 ANCHOR. C_LIO_LILAVR-289 inhibits viral replication by targeting viral DNA polymerase, preventing DBP clustering and replication center formation. C_LIO_LIIn immunosuppressed Syrian hamsters, LAVR-289 is well tolerated and ensures 100% survival while effectively stopping virus replication. C_LIO_LILAVR-289's broad-spectrum activity positions it as a promising treatment for immunocompromised patients facing multiple viral infections. C_LI

microbiology↗

bioRxiv2025

LAVR-289, a new acyclo-nucleoside phosphonate having broad-spectrum activity against herpesviruses.

Human herpesviruses are latent opportunistic large dsDNA viruses that can have deleterious effect in immunocompromised patients by triggering life-threatening infections. Over the past years, different antivirals have been developed against a variety of herpesviruses, including Acyclovir for herpes simplex viruses (HSV1 and 2) and ganciclovir and letermovir for human cytomegalovirus (hCMV). However, broad-spectrum inhibitors of herpesvirus infections are still missing. Here we report the efficacy of LAVR-289, a new acyclic nucleoside analog, on a broad variety of herpesviruses from human and animal origin. LAVR-289 displays nanomolar efficiency in vitro, is active on viral strains resistant to gold standard antivirals and ex vivo on reconstituted human skin infected with HSV1. Combined with its anti-poxvirus and anti-adenovirus activity, LAVR-289 can become the next gold standard for the management of opportunistic virus infections in immunocompromised patient.

microbiology↗